Genmab — Oktober 2017
-
hvordan det er muligt at kommunikere komplet q/q stagnation i launch af et produkt som dara kræver en speciel form for inkompetence
-
Min nemesis har skam allerede indfundet sig her på PI for meget lang tid siden
-
Janssen announced the market launch of Darzalex in Russia -
https://gmpnews.net/2017/10/first-anti-cd38-monoclonal-antibody-is-registered-in-the-russian-federation/ -
and a slightly unclear message from Janssen Australia "New immunotherapy approved for deadly form of blood cancer" http://www.medianet.com.au/releases/146811/
-
MSD trækker europæisk lungekræftansøgning tilbage
Amerikanske Merck/MSD har droppet en EU-ansøgning for sin immunterapi Keytruda i førstelinjebehandling af lungekræft. Det ses som et alvorligt tilbageslag for lægemidlet, der omsatte for mere end 1 mia. dollars i det seneste kvartal, og selskabets aktiepris dykkede markant som følge af nyheden.
(medwatch.dk)
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind